Emcure Drops Poviztra Semaglutide Starting Dose Price by 55%

In a significant development for obesity treatment in India, Emcure Pharmaceuticals has reduced the price on its starting dose of obesity drug Poviztra (semaglutide injection) by 55 per cent. This price drop on Poviztra semaglutide makes the therapy more affordable, especially as India faces a mounting obesity crisis.

Emcure's Partnership with Novo Nordisk and Poviztra Launch

Emcure has a partnership with innovator Novo Nordisk and sells its second brand of obesity drug Wegovy under its own brand name, Poviztra. As the first Indian company to exclusively distribute and commercialise Poviztra®, a second brand of Novo Nordisk's semaglutide injection for obesity, Emcure aims to expand access and enable more patients to benefit from this proven therapy at the revised price.

The price reduction will be effective from April 3, positioning Poviztra as a competitive option in the semaglutide market.

Timing of the Price Cut: Response to Market Shifts

The move comes a day after Novo Nordisk slashed prices on its Wegovy and Ozempic, both containing semaglutide. Last week has seen several Indian drugmakers launch their generic versions of semaglutide, after a patent on the drug expired in India, among other markets. The generics priced their products between 50 to 80 per cent lower than the innovator price.

This wave of affordability follows the patent expiry, opening the door for local manufacturers to provide semaglutide at substantially reduced costs compared to branded versions like Wegovy and Ozempic.

Pricing Details for Poviztra Semaglutide

Emcure said its starting dose is pegged at ₹3,999 per month. The innovator's semaglutide is available in a once-weekly pen device in five strengths: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and a maintenance dose of 2.4 mg.

• Starting Dose: Now ₹3,999 per month (55% reduction)
• Dosing Schedule: Once-weekly subcutaneous injection
• Strengths: 0.25 mg (initiation), escalating to 2.4 mg maintenance

Patients typically start at the lowest dose to minimize side effects, gradually titrating up under medical supervision.

What is Semaglutide and How Does Poviztra Work?

Semaglutide, the active ingredient in Poviztra, Wegovy, and Ozempic, is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the GLP-1 hormone, which regulates blood sugar, slows gastric emptying, and reduces appetite by signaling fullness to the brain.

For obesity management, semaglutide promotes sustained weight loss—clinical trials show average reductions of 15-20% body weight at maintenance doses. Poviztra delivers this via a user-friendly pen device, similar to Wegovy, ensuring precise weekly dosing.

Unlike short-acting GLP-1s, semaglutide's long half-life allows once-weekly administration, improving adherence for patients managing obesity or type 2 diabetes.

India's Obesity Epidemic: Why Access to Semaglutide Matters

India is grappling with a growing obesity epidemic, with nearly 254 million people living with generalised obesity and 351 million living with abdominal obesity. Improving access to a globally established molecule like semaglutide is crucial to addressing this public health challenge at scale.

Abdominal obesity, in particular, heightens risks for cardiovascular disease, type 2 diabetes, and metabolic syndrome—conditions semaglutide targets effectively. Affordable options like the new Poviztra pricing can help bridge the gap, enabling more Indians to achieve healthier weights.

Expert Insights from Emcure Leadership

"The revised pricing of Poviztra is a step towards making scientifically validated weight-management therapies more accessible and affordable to a wider patient base."

Satish Mehta, Emcure Pharma Chief Executive Officer and Managing Director

Mehta emphasized the public health imperative, noting semaglutide's proven efficacy in global trials for obesity and related comorbidities.

Safety Considerations and Side Effects of Semaglutide

While effective, semaglutide requires careful use. Common side effects include nausea, vomiting, diarrhea, and constipation, often most pronounced during dose escalation. Rare but serious risks include pancreatitis, gallbladder issues, and thyroid tumors (in animal studies).

Patients should discuss with their doctor if they have a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Starting at the low 0.25 mg dose, as with Poviztra, helps mitigate gastrointestinal issues.

For tracking symptoms or medication schedules, apps like Shotlee can assist patients in logging side effects and adherence during titration.

Who Should Consider Poviztra? Patient Guidance

Poviztra is indicated for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related conditions like hypertension or diabetes. It's not for cosmetic weight loss.

Steps to Discuss with Your Doctor:

• Assess eligibility based on BMI and comorbidities
• Review medical history for contraindications
• Plan gradual dose increases every 4 weeks
• Combine with diet, exercise, and behavioral changes for best results

Compared to generics (50-80% cheaper), Poviztra offers Novo Nordisk-backed quality assurance through Emcure's exclusive distribution.

Key Takeaways: What This Means for Patients

• Emcure's 55% price cut brings Poviztra starting dose to ₹3,999/month, effective April 3.
• Follows Novo Nordisk cuts and generic launches post-patent expiry.
• Addresses India's obesity burden: 254M generalized, 351M abdominal cases.
• Semaglutide via once-weekly pens (0.25-2.4 mg) promotes significant weight loss.
• Consult healthcare providers for personalized use; monitor side effects closely.

Conclusion: A Step Toward Accessible Obesity Care

Emcure's price reduction on Poviztra semaglutide underscores a pivotal shift in India's weight management landscape. By lowering barriers to this effective GLP-1 therapy, more patients can access tools to combat obesity. Stay informed on evolving options and prioritize medical guidance for safe, sustainable results. For related topics like GLP-1 comparisons or metabolic health strategies, explore our guides on Wegovy alternatives and semaglutide dosing.